Yichang Humanwell Pharmaceutical Co. Ltd. has identified compounds acting as potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators. They are reported to be useful for the treatment of amyotrophic lateral sclerosis, depression, epilepsy, stroke, multiple sclerosis, pain, and Alzheimer’s and Parkinson’s disease, among others.